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Abstract
Purpose Dyslipidemia is considered as one mechanism caus-
ing cardiovascular sequelae in obstructive sleep apnea (OSA).
Continuous positive airway pressure (CPAP) can reduce car-
diovascular morbidities but its effect on lipid profiles is in-
conclusive. This study aimed to investigate the effects of
CPAP on lipid profiles by a meta-analysis of the existing
randomized controlled trials.
Methods Studies were retrieved from MEDLINE/PubMed,
EMBASE, CENTRAL, commercial websites, and article ref-
erences up to August 2013 following the protocols (PROS-
PERO CRD42012002636). Randomized controlled trials in-
vestigating the CPAP effects on changes in lipid profiles in
adult patients with OSA were included. Two independent
researchers extracted relevant data in duplicate. The pooled
effect was analyzed by fixed-effect generic inverse variance,
and the heterogeneity was assessed using the I2 statistic.
Results Six trials with 348 patients and 351 controls were
included. CPAP significantly lowered total cholesterol (mean,
−6.23 mg/dl; 95% CI, −8.73 to –3.73; I2, 0 %; p<0.001),
triglyceride (mean, −12.60 mg/dl; 95% CI, −18.80 to −6.41;
I2, 25 %; p<0.001), and high-density lipoprotein (mean,
−1.05 mg/dl; 95% CI, −1.69 to −0.40; I2, 0 %; p=0.001), but
not low-density lipoprotein (mean, −1.01mg/dl; 95%CI, −5.04
to 3.02; I2, 0 %; p=0.62). The lipid-lowering effects were
homogeneous across the studies. By subgroup analysis, the
reductions of lipid profiles were associated with the cross-
over design, subtherapeutic CPAP as placebo, enrolled patients
withmoderate-to-severe OSA or daytime sleepiness, and CPAP
treatment with short-term duration or good compliance.
Conclusions This meta-analysis validates the observation that
CPAP can reduce lipid profiles in patients with OSA.
Keywords Cholesterol . Continuous positive airway
pressure . Lipoproteins .Meta-analysis . Sleep apnea,
obstructive . Triglycerides
Introduction
Obstructive sleep apnea (OSA) is common in adults, with an
estimated prevalence of 6–24 % [1]. It is characterized by
recurrent collapse of the upper airway during sleep that can
lead to chronic intermittent hypoxia and sleep fragmentation
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[2]. Evidences demonstrate that patients with OSA suffer from
higher cardiovascular morbidities and mortalities [3].
Dyslipidemia, a known risk factor of atherosclerotic car-
diovascular disease [4], has been posited to be responsible for
the cardiovascular sequelae in OSA [5–7]. The chronic inter-
mittent hypoxia in OSA can result in dyslipidemia through the
upregulation of lipid biosynthesis, promotion of peripheral
lipolysis, and suppression of lipoprotein clearance [8, 9].
Continuous positive airway pressure (CPAP) can reduce the
risk of cardiovascular sequelae [3], but the exact mechanisms
have not been fully elucidated where the reversal of dyslipid-
emia may be a crucial mechanism [8–11].
Studies evaluating the effects of CPAP on lipid metabolism
had conflicting results. Most are observational and small-sized
and without proper controls [12]. Although several random-
ized controlled trials (RCTs) have overcome such shortcom-
ings, the results remain inconclusive. The discrepancies be-
tween these RCTs are related to the heterogeneity of partici-
pants, duration of CPAP treatment, placebo selections, small
sample size, and lipid profile not set as the primary outcome
[12]. To date, there have been two studies using meta-analysis
to approach this issue. Robinson’s study composed of only
two RCTs that meta-analyzed the pooled effects of CPAP on
lipid profiles published one decade ago [13]. Another, Xu’s
study, which was registered after ours (PROSPERO No.
CRD42013005732) and published recently, included six
RCTs for meta-analysis [14]. However, this study improperly
included Kohler’s study which used CPAP withdrawal design
[15] and Sharma’s study which was retracted [16]. It could
lead to questionable results and conclusion. In addition, the
study’s design and control type were not investigated of their
confounding effects. Therefore, we reported our study here by
meta-analysis of RCTs to investigate the effects of CPAP on




The data extraction was conducted in duplicate by two inde-
pendent researchers. When the results were inconsistent, a
third person was invited and the decision was made by the
majority.
The flow chart of data extraction (Fig. 1) showed that a
web-based search was first conducted in the bibliographic
databases of PubMed/MEDLINE, EMBASE, and the
Cochrane Central Register of Controlled Trials (CENTRAL)
updated to August 2013 using following strategies: (1) MeSH
term approach: (“sleep apnoea, obstructive” [MeSH]) AND
(“continuous positive airway pressure” [MeSH]) AND (“met-
abolic diseases” [MeSH] OR lipids [MeSH] OR cholesterol
[MeSH] OR triglycerides [MeSH] OR lipoproteins [MeSH]);
(2) direct keyword approach: (“obstructive sleep apnoea” OR
OSA OR “obstructive sleep apnoea syndrome” OR OSAS)
AND (“continuous positive airway pressure” OR CPAP)
AND (dyslipidemia OR lipid(s) OR triglyceride(s) OR lipo-
protein(s) OR LDL OR HDL ORTG OR “metabolic disease”
OR cholesterol(s)). No limitation was set.
The ongoing or unpublished studies were accessed
via the international trials register (Clinicaltrials.gov/)
and the UMI Dissertation (ProQuest Dissertation and
Theses Database). A commercial Internet search engine
(Google®) was also searched using the same strategy.
Additional publications were excluded from identified
references.
Second, the titles and abstracts of identified studies were
screened for potentially pertinent (containing any direct or
indirect relevance to CPAP effect on lipid profiles), which
were then retrieved from the full text. Studies were considered
eligible for meta-analysis if they fulfilled all of the following
criteria: (1) subjects were age ≥18 years old; (2) the study
participants were diagnosed as OSA by polysomnography
where apnea-hypopnea index (AHI), respiratory disturbance
index (RDI), or oxygen desaturation index (ODI) was >5/h;
(3) the studies were designed as RCT trials; (4) CPAP was the
intervention; (5) lipid profiles, including total cholesterol (T-
CHO), triglyceride (TG), high-density lipoprotein (HDL), and
low-density lipoprotein (LDL), were the outcomes of CPAP
treatment. Unpublished studies or studies without extractable
outcome were excluded.
Coding
The full texts of included papers were thoroughly
reviewed, and the parameters were retrieved following
the protocols (http://www.crd.york.ac.uk/PROSPERO/
disp lay_record .asp?ID=CRD42012002636) . The
information extracted included parameters on (1) study
conditions, including sample size, source of participants,
study design, and end points; (2) patient characteristics,
including race, age, sex, body mass index (BMI), comor-
bidity, maintenance medications, OSA severity, daytime
sleepiness, and use or non-use of lipid-lowering agents;
(3) CPAP interventions including duration, categorized as
long term (≥12 weeks) or short term (<12 weeks), and
compliance, with average use ≥4 h/night as good compli-
ance [17]; (4) levels of T-CHO, TG, HDL, and LDL at
baseline and at the end of the trials; and (5) BMI and blood
pressure (BP) before and after CPAP treatments.
The severity of OSAwas categorized as moderate to severe
if AHI or RDI was ≥15/h or ODI was >10/h [18]. Daytime
sleepiness was assessed using the Epworth Sleepiness Scale
(ESS), where sleepiness was defined as ESS ≥10.
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Risk of bias assessment
The risk of bias of the included studies was assessed from six
domains: sequence generation, allocation concealment,
blinding, incomplete outcome data, selective outcome
reporting, and other issues [19].
Statistical analysis
The software used for analysis included STATA software 9
(STATA Corporation, College Station, TX) and ReviewMan-
ager (RevMan) 5.1.6 (Nordic Cochrane Centre, Copenhagen,
Denmark). The serum levels of T-CHO, TG, HDL, and LDL
were presented as mean±standard deviation (SD) with 95 %
confidence interval (95% CI) in milligrams per deciliter. The
effective size was mean differences in changes of T-CHO, TG,
HDL, and LDL between the CPAP and control groups. The
variance of mean differences was calculated as Elbourne’s
study [20].
The statistical heterogeneity was assessed using the I-
square statistic (significance was set at I-square >75 %). The
Dersimonian and Laird random effect models were used
to evaluate differences in changes. Sensitivity analysis
was applied to assess the robustness of the studies’
results when information was inadequate. The contour-
enhanced plot with the trim and fill adjustments was
used to assess publication bias [21].
Subgroup analysis and meta-regression were used to eval-
uate possible sources of bias, including study design (cross-
over and control selection), age, sex, BMI, comorbidity, med-
ications, OSA severity, daytime sleepiness, CPAP duration
and compliance, baseline levels of T-CHO, TG, HDL, and
LDL, and change in BP before and after CPAP treatment.
Results
Search results
Data extraction identified 145 potentially relevant studies
(Fig. 1), and six RCTs with a total of 348 patients and 351
controls were finally enrolled after filtering with the inclusion
and exclusion criteria.
Trial characteristics
The characteristics of the six trials were summarized (Table 1).
The sample number was <50 in four trials [22–25], and all of
the participants were recruited from hospitals. Three studies
were cross-over and three were parallel [13, 24, 26]. Three
trials used therapeutic CPAP as placebo [13, 22, 25], while
others used no treatment as controls.
The specifications for enrolment in the six trials included
recruitment of patients with minimal symptoms in two [26,
References identified through 
PubMed/Medline, EMBASE and 
CENTRAL n = 649
References identified through 
Google® or reference of 
citations n = 2
References screened n = 455
References included in 
meta-analysis n =6
Ongoing or unpublished studies 
identified through Clinicaltrials.gov 
and UMI Dissertation n= 8
Duplicate references n = 204
References excluded
Pediatric OSA studies n=4
Not original studies   n=61
Non-RCTs n=58
RCTs n=8
CPAP withdrawal study n=1
Not interested outcome* n=6
Retraction n=1
Non-published study n=8
References for detailed evaluation
and screened by inclusion and 
exclusion criteria n = 145
References excluded:
Not relevant to CPAP effects on 
lipid profiles n = 310




pressure, OSA obstructive sleep
apnea. Asterisk indicates one
study included without
extractable outcome
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23], free of comorbidities in one [24], no medications in two
[25, 24], and exclusion of patients with substantial hypersom-
nolence in one [23]. In general, the participants were obese,
middle-aged men with daytime sleepiness, and had comorbid-
ities like hypertension (51 %) and diabetes (9 %). All except
one trial included subjects with moderate-to-severe OSA [26].
Race was not specified in all of the trials.
The duration of CPAP treatment varied from weeks to
months, including two long-term [26, 24] and four short-term.
Compliance to CPAP was good in five and poor in two [25,
26].
Four studies addressed changes in BMI, where BMI de-
creased in one [26] and did not change in three [25, 24, 22].
Changes in blood pressure were reported in four trials, in
which blood pressure decreased in two [25, 24], did not
change in one [23], and increased in one [26].
Risk of bias assessment
The heterogeneities of the enrolled studies (Fig. 2; Supple-
mental S1) revealed that five studies [25, 26, 5, 22, 13]
properly randomized their participants and one did not men-
tion details of the randomization [23]. Four studies reported
the allocation procedure and blindness [13, 25, 26, 22]. Per-
formance bias was marked as high risk in three studies [23, 26,
24] that did not use subtherapeutic CPAP as control. Attrition
bias was noted in two studies reporting >20 % dropout rate
[26, 22] and in one study with >50 % missing data without
explanation [13].
Main findings
The changes in T-CHO, TG, HDL, and LDL are shown in
Table 2. The heterogeneity among studies analyzing T-CHO
(I2 0 %), TG (I2 25 %), HDL (I2 0 %), and LDL (I2 0 %) were
all low (Fig. 3). After applying the fixed model to determine
the difference in changes between the CPAP treatment and
control groups, the overall reduction was significant in T-










































































































































































































































































































































































































































































































































































































































































































































































































Fig. 2 Summary figure of risk of bias. Plus mark (+) low risk of bias,
minus mark (−) high risk of bias, question mark (?) unclear risk of bias
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−3.73 mg/dl, p<0.001) (Fig. 3a), TG (mean −12.60 mg/dl,
95% CI −18.80 to −6.41 mg/dl, p<0.001) (Fig. 3b), and HDL
level (mean −1.05 mg/dl, 95% CI −1.69 to −0.40 mg/dl, p=
0.001) (Fig. 3c). The LDL level was not affected by CPAP
(mean −1.01 mg/dl, 95% CI −5.04 to 3.02, p=0.62) (Fig. 3d).
The subgroup analysis (Supplemental S2) revealed that
CPAP lowered T-CHO, TG, and HDL in studies with cross-
over design, subtherapeutic CPAP as placebo, moderate-to-
severe OSA, daytime sleepiness, short-term CPAP treatment,
use of lipid-lowering agents, good compliance to CPAP, and
low risk of bias (Supplemental Figs. S2a–c). This was not seen
in LDL (Supplemental Fig. S2d).
Meta-regression showed that the TG-lowering effect in-
creased in studies with shorter CPAP duration (β=0.87, p=
0.029) and with more patients with hypertension (β=0.23, p=
0.049) and cardiovascular disease (β=2.30, p=0.040) (Sup-
plemental Table S4A).
There was no major publication bias observed (Supple-
mental S3).
Sensitivity analysis
After excluding Phillip’s study [22], which weighed more
than 50 %, the CPAP effect on HDL (mean −0.78 mg/dl,
95% CI −1.95 to 0.38 mg/dl, p=0.19) became insignificant.
After excluding three studies with performance bias [23, 26,
24] and two studies with attribution bias [26, 13], the CPAP
effects on lipid profiles did not change. Excluding the studies
reporting changes in BMI [23, 26, 13], the CPAP effect on all
lipid profiles remained unchanged (Supplemental Table S4B).
Discussion
This study aimed to clarify the effects of CPAP on lipid
profiles in patients with OSA through the meta-analysis of
the RCTs updated toAugust 2013. Six RCTswith 348 patients
and 351 controls were analyzed. Most of the participants were
middle-aged, obese males with moderate-to-severe OSA. The
results demonstrated that CPAP therapy significantly lowered
T-CHO, TG, and HDL levels where these effects were homo-
geneous among studies. The subgroup analysis showed that
the reduction in lipid profiles was associated with a cross-over
design, subtherapeutic CPAP as placebo, enrolment of pa-
tients with moderate-to-severe OSA or daytime sleepiness,
and CPAP treatment with short-term duration or good
compliance.
The evidence towards such conclusion is strong when
assessing using the GRADE approach (Supplemental S5).
Compared to Robinson’s meta-analysis [13], this study sys-
temically reviewed updated evidence and studied the CPAP
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meta-analysis did not enroll Kohler’s study, which investigat-
ed the change of lipid profiles after withdrawal of CPAP [15].
We also excluded Sharma’s study [27], which was retracted
due to transcription errors on the assessment of abdominal fat,
although these errors did not affect the blood sampling of lipid
profiles [16]. Even including Sharma’s study, the CPAP effect
on lipid profiles remained unchanged (Supplemental
Table S4B). Besides, we found another two studies [24, 22]
which were relevant to this issue but not included in Xu’s
study. Furthermore, the confounding effects of the study’s
design or control type were investigated in our study by
subgroup analysis.
A number of studies have investigated the effect of CPAP
on lipid profiles, but the results were rather conflicting [12].
Majority of these studies were observational studies, which
was easily confounded by unmeasured factors. For example,
positive studies mostly revealed that CPAP could improve T-
CHO and TG levels in OSA patients with weight reduction,
good CPAP adherence, or initial abnormal lipid profile [17,
28–31]. Negative studies often had small sample size or
lacked information of CPAP compliance [32–34]. In contrary,
present study meta-analyzed the RCTs which could eliminate
those confounders and drew the solid conclusion of the lipid-
lowering effect of CPAP.
Our result showed that CPAP had only modest effect on T-
CHO and TG, minimal on HDL, and no effect on LDL. In one
recent study, the meta-regression analysis showed the AHI
had significant effect for LDL and TG while age had signif-
icant effect for T-CHO, LDL and HDL, and BMI had signif-
icant effect for LDL and HDL [35]. Our study only recruited
RCTs where the CPAP effect on lipid profiles was rather
related on reversal of apnea-hypopnea than confounders like
age and BMI. This may explain why CPAP had a greater
impact on TG level than other lipid profiles in the present
study. Moreover, our finding that HDL decreased after CPAP
treatment echoed the findings in Cuhadaroglu’s study [31] but
Fig. 3 Fixed-effect meta-analysis
of continuous positive airway
pressure (CPAP) effects on lipid
profiles in obstructive sleep apnea
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contradicted other observational studies [36, 28]. All of these
studies, designed as before-after series, had no proper control.
Previous studies also noted that OSA patients who adhered to
CPAP were more compliant in refilling their lipid-lowering
medications [37]. Thus, using before-after series studies to
investigate CPAP effects would be biased towards the more
beneficial effects on HDL. In the current meta-analysis, even
after confounders originating from lifestyle were controlled in
RCTs or after excluding an influential study with high weight
[22], CPAP still had no benefits on HDL.
Although CPAP is beneficial for affecting lipid metabo-
lism, the magnitude of lipid reduction is modest (3.0 % for T-
CHO, 6.7 % for TG, 3.1 % for HDL, and 1.2 % for LDL)
compared to the effect of anti-lipid agents (>30 %) [38]. To
estimate the 10-year risk of developing coronary heart disease
based on the Framingham study score system [39], such
reduction in lipid profiles only represent about 1~2 % of
vascular disease risk reduction. Lipid-lowering drugs are still
needed to treat dyslipidemia in OSA. On the other hand, the
subgroup analysis here shows that the lipid-lowering effects
are also noted in studies where participants are allowed to use
lipid-lowering agents, which may support the synergistic ef-
fect of CPAP and lipid-lowering agents like valsartan to
reduce BP [40]. Further studies to elucidate whether CPAP
interacts with lipid-lowering agents to enhance their effects
are warranted.
The studies with cross-over design or those that use sub-
therapeutic CPAP as control show more prominent lipid-
lowering effects. This is related to the less heterogeneity of
participants in the cross-over design and minimal lifestyle-
related confounders with subtherapeutic CPAP as control. The
lipid-lowering effects are more significant in studies recruiting
participants with moderate-to-severe OSA or daytime sleepi-
ness. The former is associated with more episodes of intermit-
tent hypoxia [41], one proposed mechanism causing dyslip-
idemia in OSA [8]. Hence, CPAP, by reverting intermittent
hypoxia, can have greater impact on relieving dyslipidemia.
The study of Barcelo et al. supports the view that daytime
sleepiness is a useful marker for CPAP effect on cholesterol
[42]. Moreover, the present meta-regression shows that the
lipid-lowering effects are decreased in studies enrolling more
patients with hypertension or cardiovascular disease. This
may be because dyslipidemia in these patients can be induced
by causes other than intermittent hypoxia, so the effects of
CPAP on lipid profiles are compromised. The study of Kumor
et al. reports the same phenomenon that CPAP decreases lipid
concentration only in pure OSA, not in OSA with ischemic
heart disease [43].
Several studies have proposed that CPAP compliance will
impact the effects of CPAP on lipid metabolism [29, 44, 17].
This study confirms the observation that CPAP can lower lipid
profiles in patients using CPAPmore than 4 h per night. In the
present study, the duration of CPAP treatment is inversely
correlated to the CPAP effect on lipid profiles, which may
be due to the influence of confounders other than CPAP, such
as diet or exercise, which increases as the trial period becomes
longer.
The risk of bias also influences the effects of CPAP on lipid
profiles, especial performance bias. It may be related to the
cross-over design or use of subtherapeutic CPAP, as previous-
ly mentioned.
The exact mechanism how CPAP improved lipid metabo-
lism was not clear. The elimination of chronic intermittent
hypoxia and sympathetic hyperactivity, two hallmarks of
OSA, had been proposed as mechanisms. In animal model,
chronic intermittent hypoxia had been demonstrated to pro-
mote dyslipidemia through upregulating the transcriptional
factor, sterol regulatory element-binding protein-1, and down-
stream enzyme of triglyceride and phospholipid biosynthesis,
stearoyl-CoA desaturase-1 [45]. Catecholamine could pro-
mote gluconeogenesis, peripheral insulin resistance, and lipol-
ysis [46]. Therefore, by reversing the intermittent hypoxia and
sympathetic hyperactivity, CPAP could improve dyslipid-
emia. In addition, by improving the hypersomnolence, CPAP
could increase daytime physical activity and caloric expendi-
ture which helped to improve dyslipidemia [47].
Previous studies suggested that intermediary mechanisms,
like inflammation or sympathetic activation, may take part in
linking intermittent hypoxia to dyslipidemia [46]. To explore
the influence of inflammatory mediators and sympathetic
hyperactivity on fat metabolism, we extracted parameters
associated with inflammation or autonomic stress (Supple-
ment S2, Table S2A-S2B) which included three studies re-
garding inflammatory mediators [23, 24, 13] and four regard-
ing autonomic system [22–25]. Thereafter, we studied the
effect size of lipid profiles through stratifying studies as con-
taining inflammatory mediators or autonomic activity marker.
The result showed that the CPAP lipid-lowering effect on T-
CHO, TG, and HDL was only significant in studies where
autonomic hyperactivity was also lowered by CPAP. The
correlation between change in inflammatory parameters and
the effect of CPAP on lipid profiles could not be concluded
because only a few of recruited studies provided such infor-
mation. However, one recent study by Joyeux-Faure showed
that the statin therapy known for anti-inflammatory effect had
no effect on inflammatory or autonomic activity markers
despite its lipid-lowering effect [48].
This study has some limitations. First, the lipid profileswere
not the primary outcomes in the majority of the studies includ-
ed. Information on some important confounding factors like
diet, physical activity, and body composition during the study
period was not addressed [12]. Instead, changes of BMI were
used as the surrogate of change in lifestyle during the trials.
Even excluding studies reporting changes of BMI during the
trial period, the effects of CPAP on lipid profiles remained
unchanged. Secondly, all recruited study had CPAP duration
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less than 24 weeks, so the results could not be applied to those
on CPAP more than 24 weeks. Lastly, difference in blood
sampling timing (fasting or non-fasting) was noted between
included studies, and this difference was equally distributed in
the intervention and control groups because of the randomiza-
tion procedure. Therefore, it should not bias our comparison.
Conclusions
The independent benefits of CPAP on lipid profiles, including
T-CHO and TG-lowering effects, are confirmed in this meta-
analysis. The benefits are consistent among studies but are
particularly prominent in patients with moderate-to-severe
OSA, daytime sleepiness, good compliance to CPAP, or
short-duration CPAP treatment. The cross-over design and
use of subtherapeutic CPAP, which can influence the risk of
bias, are factors affecting the effects of CPAP on lipid profiles.
The benefit to HDL by CPAP is not proven. Due to the modest
benefits of CPAP, lipid-lowering agents are still needed for
better control of abnormal lipid levels in patients with OSA.
Both CPAP and lipid-lowering agents may have synergistic
effect, which warrants further studies.
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